Cognetivity Neurosciences (STU:1UB) Debt-to-Equity: -0.09 (As of Oct. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cognetivity Neurosciences Debt-to-Equity?

Cognetivity Neurosciences STU:1UB Debt-to-Equity is -0.09 as of Oct. 2023.

Cognetivity Neurosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2023 was €0.95 Mil. Cognetivity Neurosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2023 was €0.00 Mil. Cognetivity Neurosciences's Total Stockholders Equity for the quarter that ended in Oct. 2023 was €-10.49 Mil. Cognetivity Neurosciences's debt to equity for the quarter that ended in Oct. 2023 was -0.09.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cognetivity Neurosciences's Debt-to-Equity or its related term are showing as below:

STU:1UB's Debt-to-Equity is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 0.43
* Ranked among companies with meaningful Debt-to-Equity only.

Cognetivity Neurosciences  (STU:1UB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cognetivity Neurosciences Debt-to-Equity Related Terms

Cognetivity Neurosciences Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Cognetivity Neurosciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cognetivity Neurosciences Debt-to-Equity Chart

Cognetivity Neurosciences Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23
Debt-to-Equity
Get a 7-Day Free Trial 0.00 -1.17 0.36 -0.23 -0.13

Cognetivity Neurosciences Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.21 -0.13 -0.12 -0.10 -0.09

STU:1UB vs VEEV, GEHC, HQY: Debt-to-Equity Comparison

For the Health Information Services subindustry, Cognetivity Neurosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cognetivity Neurosciences Debt-to-Equity vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cognetivity Neurosciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cognetivity Neurosciences's Debt-to-Equity falls into.


Cognetivity Neurosciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cognetivity Neurosciences's Debt to Equity Ratio for the fiscal year that ended in Jan. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.893 + 0) / -6.838
=-0.13

Cognetivity Neurosciences's Debt to Equity Ratio for the quarter that ended in Oct. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.945 + 0) / -10.494
=-0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.09 mean?
Cognetivity Neurosciences (STU:1UB) has a Debt-to-Equity of -0.09 as of Oct. 2023. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cognetivity Neurosciences and its competitors.
Is Cognetivity Neurosciences' Debt-to-Equity too high?
Cognetivity Neurosciences' current Debt-to-Equity is -0.09.
How does Cognetivity Neurosciences' Debt-to-Equity compare to VEEV and GEHC?
Cognetivity Neurosciences' Debt-to-Equity of -0.09 can be compared against companies in the Healthcare Providers & Services industry. The industry median Debt-to-Equity is 0.43. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.43, based on 561 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cognetivity Neurosciences and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cognetivity Neurosciences's current Debt-to-Equity is -0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cognetivity Neurosciences stock overvalued right now?
Cognetivity Neurosciences (STU:1UB) has a current Debt-to-Equity of -0.09. The current Debt-to-Equity is -0.09. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Cognetivity Neurosciences (STU:1UB), the current Debt-to-Equity is -0.09 as of Oct. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cognetivity Neurosciences Business Description

Address 800 West Pender Street, Suite 1430, Vancouver, BC, CAN, V6C 2V6
Cognetivity Neurosciences Ltd is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial, and consumer environments for potentially allowing early diagnosis of dementia. The Company is considered operating in one segment for development of the ICA platform. Its geographical areas include Canada, United Kingdom and Dubai.